Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Leyla O. Shune, Ayman Qasrawi, Gerhard C Hildebrandt, Eric J Huselton, Howard Langstein, Dennis Allin, Kaitlyn Burrows, Andrea M Baran, Jane L. Liesveld, Neil Blumberg, Brea Lipe, Andrew G Evans, Derick R Peterson, Omar Aljitawi

Blood (2024) 144 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2024-211184

Published: 2024

Journal Articles

Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)

Clare B Heffernan, Charles C Chu, Jennifer E Bruno, Christine A Herne, Andrea M Baran, Ronald P Taylor, Paul M. Barr, Michael R. Elliott, Clive S Zent

Blood (2023) 142 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2023-175019

Published: 2023

Journal Articles

Splenic B Cell Lymphoma Innate Immune Cells: Detection of Red Versus White Pulp Lymphoma Differences in NK Cell Populations By High-Parameter Flow Cytometry

Christine A Herne, Jennifer E Bruno, Andrea M Baran, Derick R Peterson, Audrey H Chung, Tim R Mosmann, Sally A Quataert, Andrew G Evans, Walter R Burack, Clive S Zent, Charles C Chu

Blood (2023) 142 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2023-181081

Published: 2023

Journal Articles

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial

Leyla Shune, Ayman Qasrawi, Gerhard Hildebrandt, Eric J Huselton, Howard Langstein, Dennis Allin, Kaitlyn Burrows, Andrea M Baran, Jane L. Liesveld, Neil Blumberg, Brea Lipe, Andrew G Evans, Derick R Peterson, Omar Aljitawi

Blood (2023) 142 (Supplement 1): 2221.

https://doi.org/10.1182/blood-2023-190079

Published: 2023

Journal Articles

Denosumab for the Treatment of Smoldering Multiple Myeloma: Rates of Osteoporosis and Change in Lowest T-Score after 12 Months of Treatment

Jodi Jacklyn Lipof, Andrea M Baran, Frank Charles Passero, Kaitlyn Burrows, Brea Lipe

Blood (2022) 140 (Supplement 1): 12645–12646.

https://doi.org/10.1182/blood-2022-168297

Published: 2022

Journal Articles

The Role of Splenectomy in Management of Splenic B-Cell Lymphomas

William J Archibald, Andrea M Baran, Annalynn M Williams, Chauncey Syposs, Rabih M Salloum, Andrew G Evans, Clive S. Zent

Blood (2022) 140 (Supplement 1): 11964–11965.

https://doi.org/10.1182/blood-2022-165496

Published: 2022

Journal Articles

Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment

Christine A. Herne, Jennifer E. Bruno, Andrea M Baran, Derick R. Peterson, Tim R. Mosmann, Sally A. Quataert, Andrew G Evans, Charles C. Chu, Clive S. Zent

Blood (2022) 140 (Supplement 1): 3585–3586.

https://doi.org/10.1182/blood-2022-167563

Published: 2022

Journal Articles

Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Marissa Locastro, Chandrika Sanapala, Jason H. Mendler, Sally Norton, Rachelle Bernacki, Thomas Carroll, Heidi Klepin, Erin Watson, Jane L. Liesveld, Eric J. Huselton, Kristen M. O'Dwyer, Andrea M Baran, Marie Flannery, Benzi Kluger, Kah Poh (melissa) Loh

Blood (2022) 140 (Supplement 1): 10839–10840.

https://doi.org/10.1182/blood-2022-165583

Published: 2022

Journal Articles

Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Karl R. VanDerMeid, Paul M. Barr, Alyssa R. Williams, Sally A. Quataert, Clive S. Zent, Charles C. Chu

Blood (2022) 140 (Supplement 1): 4121–4122.

https://doi.org/10.1182/blood-2022-169403

Published: 2022

Journal Articles

Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Clive S. Zent, Jeremiah E. Moore, Paige C. Bloom, Charles C. Chu, Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Sally A. Quataert, Tim R. Mosmann, Ronald P. Taylor, Danielle S. Wallace, Michael R. Elliott, Paul M. Barr

Blood (2022) 140 (Supplement 1): 4171–4172.

https://doi.org/10.1182/blood-2022-162858

Published: 2022

Journal Articles

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Danielle S. Wallace, Andrea M. Baran, Jonathan W. Friedberg, Patrick M. Reagan, Carla Casulo, Mijamin Friend, Alyssa R. Williams, Peter D Dakin, Clive S. Zent, Paul M. Barr

Blood (2021) 138 (Supplement 1): 2640.

https://doi.org/10.1182/blood-2021-145490

Published: 2021

Journal Articles

Characterizing Naked Nuclei Frequency and Movement in Primary AML Cell Culture Using an ECM-Based Model

Shireen J. Usman, Thomas Conley, Hannah E. Whitehead, Wojciech Wojciechowski, Kaye Thomas, Dan Bergstralh, Andrea M. Baran, Andrew G Evans, Yurong Gao, Charles C. Chu, Hani Awad, Jason H. Mendler, Michael W. Becker, Omar S. Aljitawi

Blood (2021) 138 (Supplement 1): 2365.

https://doi.org/10.1182/blood-2021-149645

Published: 2021

Journal Articles

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Marissa Locastro, BS, Kah Poh Loh, MBBCHBAO, Andrea M. Baran, MS, Jane L. Liesveld, MD, Michael W. Becker, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Omar S. Aljitawi, MD, Megan Baumgart, MD, Eric Snyder, Benzi Kluger, MD, Jason H. Mendler, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139475

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Jodi J Lipof, MD, Dharmini Manogna, MD, Andrea M. Baran, MS, Bassil Said, MD, Michael W. Becker, MD, Jason H. Mendler, MD PhD, Omar S. Aljitawi, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Richard Burack, MD PhD, Margaret Blaney, Taylor Douglas, Jane L. Liesveld, MD, Kah Poh Loh, MBBCHBAO

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136739

Published: 2020

Journal Articles

A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

Patrick M. Reagan, MD, Craig A. Portell, MD, Carla Casulo, MD, Andrea M. Baran, MS, Allison Magnuson, DO, Paul M. Barr, MD, Yelena Lerman, PhD, Krista N French, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140384

Published: 2020

Journal Articles

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Charles C. Chu, PhD, Jonathan J. Pinney, PhD, Sara K. Blick-Nitko, MS, Andrea M. Baran, MS, Derick R. Peterson, PhD, Hannah E. Whitehead, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Karl R. VanDerMeid, BS, Michael Rusty Elliott, PhD, Clive S. Zent, MD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-139483

Published: 2020

Journal Articles

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Shuo Ma, MD PhD, Clive S. Zent, MD, Andrea M. Baran, MS, Andrew Bui, Philip J Meacham, PhD, Ashley Morrison, RN, Kelsey Holkovic, RN, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Michael S. Weiss, Jonathan W. Friedberg, MD MSSc, Brian T. Hill, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134818

Published: 2020

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma

Patrick M. Reagan, MD, Andrea M Baran, MS, Matthew J. Maurer, MS, Andrew L. Feldman, MD, Thomas M. Habermann, MD, Susan L. Slager, PhD, Gita Thanarajasingam, MD, Kathleen J Yost, PhD, Brian K. Link, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2018) 132 (Supplement 1): 3579.

https://doi.org/10.1182/blood-2018-99-118356

Published: 2018

Journal Articles

High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors

Annalynn M Williams, MS, Andrea M Baran, MS, Philip J Meacham, MS, Megan Herr, BS, Hugo E. Valencia, MD, Catherine Newsom, Nealansh Gupta, Michelle Janelsins, PhD, Paul M. Barr, Clive S Zent, MD

Blood (2016) 128 (22): 3203.

https://doi.org/10.1182/blood.V128.22.3203.3203

Published: 2016

NARROW

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)

Splenic B Cell Lymphoma Innate Immune Cells: Detection of Red Versus White Pulp Lymphoma Differences in NK Cell Populations By High-Parameter Flow Cytometry

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial

Denosumab for the Treatment of Smoldering Multiple Myeloma: Rates of Osteoporosis and Change in Lowest T-Score after 12 Months of Treatment

The Role of Splenectomy in Management of Splenic B-Cell Lymphomas

Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment

Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Characterizing Naked Nuclei Frequency and Movement in Primary AML Cell Culture Using an ECM-Based Model

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma

High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only